Relypsa Announces Fourth Quarter and Full Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results

REDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP ), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014.

Cash, cash equivalents and short-term investments totaled $135.8 million at December 31, 2014, compared to $94.8 million at December 31, 2013. Shares outstanding as of December 31, 2014 were 35.0 million. Cash, cash equivalents and short-term investments at December 31, 2014 on a pro forma basis to include the impact of the company's first quarter 2015 activity under its at-the-market offering and an underwritten offering was approximately $349.5 million.

Research and development expenses for the fourth quarter of 2014 were $16.6 million, compared to $10.9 million for the comparable period in 2013. Research and development expenses for the full year 2014 were $50.2 million, compared to $59.0 million in 2013. The increase for the fourth quarter was primarily driven by the New Drug Application fee and an increase in personnel expenses to support expanding operations. The decrease for the full year was primarily due to expenses incurred during the 2013 period related to a one-time $12.5 million milestone payment to Amgen and Relypsa's pivotal Phase 3 and 52-week Phase 2 clinical trials of Patiromer for Oral Suspension (Patiromer FOS) that completed during 2013, partially offset by increases in personnel expenses.

General and administrative expenses for the fourth quarter 2014 were $10.5 million, compared to $3.7 million for the comparable period in 2013. General and administrative expenses for the full year 2014 were $27.9 million, compared to $11.9 million in 2013. The increase for both the fourth quarter and full year was primarily due to an increase in personnel expenses to support expanding operations and an increase in commercial, marketing and medical affairs activities in preparation for a potential commercial launch of Patiromer FOS. 

Net loss attributable to common stockholders for the fourth quarter 2014 was $27.6 million, or $0.80 per share, compared to $9.1 million, or $0.68 per share, for the comparable period in 2013.  The increase was primarily due to a decrease in fair value of convertible preferred stock warrants during 2013 and an increase in operating expenses during 2014, partially offset by a deemed dividend to preferred stockholders due to the issuance of warrants as part of the company's Series C-2 Preferred Stock financing in October 2013.

Net loss attributable to common stockholders for the full year 2014 was $79.9 million, or $2.43 per share, compared to $81.2 million, or $22.42 per share, in 2013. The decrease was primarily due to a deemed dividend to preferred stockholders due to the issuance of warrants as part of the company's Series C-2 Preferred Stock financing in October 2013, partially offset by an increase in operating expenses during 2014.

Financial Outlook

For the full year 2015, Relypsa expects operating expenses in the range of approximately $180.0 to $200.0 million, including stock-based compensation of approximately $10.0 to $15.0 million. The 2015 operating expenses will be primarily driven by ongoing development activities as we pursue regulatory approval of Patiromer FOS, expansion of commercial launch preparation activities related to Patiromer FOS, including significant headcount growth and the manufacture of commercial supply, and increases in our general and administrative infrastructure.

"In 2014 we successfully executed against key business objectives towards bringing Patiromer for Oral Suspension to patients in need. Our NDA was accepted by the FDA in December, with a PDUFA action date of October 21, 2015. With this progress, along with a December 31, 2014 pro forma cash position of approximately $350 million, we are very pleased with our momentum heading in to 2015," said John A. Orwin, president and chief executive officer of Relypsa. "Our top priorities remain the regulatory review process and market readiness activities, including the expansion of our commercial and manufacturing infrastructures, in order to optimize our therapy and organization's positioning ahead of potential approval."

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.  A New Drug Application for Patiromer for Oral Suspension, Relypsa's lead product candidate for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood, was accepted by the U.S. Food and Drug Administration and is currently under review. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030.  More information is available at www.relypsa.com .

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Relypsa, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding expected operating expenses for the full year 2015, expected stock-based compensation for the full year 2015, the potential FDA approval of Patiromer FOS, the expected PDUFA action date, the top priorities for Relypsa and the potential commercial launch.  Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Relypsa's regulatory filings, Relypsa's substantial dependence on Patiromer FOS, Relypsa's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Patiromer FOS. Relypsa undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Relypsa in general, see Relypsa's current and future reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014 and, its Annual Report on Form 10-K for the year ended December 31, 2014.

-see attached financial tables-

Relypsa, Inc.
Statement of Operations Data
(In thousands, except share and per share amounts)
(unaudited)
         
  Three Months Ended Year Ended
  December 31, December 31,
  2014 2013 2014 2013
         
Operating expenses:        
Research and development $16,596 $10,914 $50,227 $58,971
General and administrative 10,486 3,732 27,914 11,940
Total operating expenses 27,082 14,646 78,141 70,911
         
Loss from operations (27,082) (14,646) (78,141) (70,911)
         
Interest and other income (expense), net 69 13,314 149 (1,481)
Interest expense (635) (407) (1,896) (1,453)
         
Net loss (27,648) (1,739) (79,888) (73,845)
Deemed dividend to preferred stockholders — (7,336) — (7,336)
Net loss attributable to common stockholders  $ (27,648)  $ (9,075)  $ (79,888)  $(81,181)
Net loss per share attributable to common stockholders, basic and diluted  $ (0.80)  $ (0.68)  $ (2.43)  $ (22.42)
Weighted average common shares used to compute net loss per share attributable to common stockholders, basic and diluted 34,368,776 13,430,244 32,837,508 3,620,235
         
         
Relypsa, Inc.
Condensed Balance Sheet Data
(In thousands)
     
  December 31, December 31,
  2014 2013 (1)
  (unaudited)  
     
Cash, cash equivalents and short-term investments $135,757 $94,759
     
Working capital $122,291 $78,828
     
Total assets $151,839 $106,031
     
Stockholders' equity $118,461 $74,850
     
(1) Derived from the audited financial statements

CONTACT: Alex Dobbin Associate Director, Investor Relations 650-421-6879 IR@relypsa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 23

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 119

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 62

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 26

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 20

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 75

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 108

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Green Lumber Recall Raises a Serious Safety Question

Updated Category News Views 41

A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...

Continue Reading

Top 5 Most Recently Viewed Articles

Harnessing AI for a Transformative Future in Human Resources

Updated Category News Views 193

The Impact of AI on Human Resources in 2026 As we look towards the future of work in 2026, the influence of artificial intelligence (AI) on human resources (HR) is undeniable. Businesses worldwide are adapting to an ecosystem increasingly shaped by AI, which plays a critical role in improving workforce efficiency. With insights from industry experts at ADP, organizations...

Continue Reading
Collins Aerospace Expands Executive Aircraft Seating Operations

Updated Category News Views 110

Collins Aerospace Expands Executive Aircraft Seating Operations Doubled production floor space and new machinery improves capacity and customization opportunities Collins Aerospace, a business unit of RTX (NYSE: RTX), is enhancing its executive aircraft seating facility with a significant $2 million investment. This expansion doubles the upholstery production floor space...

Continue Reading
Celebrating Success: Beyond Finance's Commitment to Clients

Updated Category News Views 345

Beyond Finance's Recognition for Outstanding Customer Service Beyond Finance, a leading name in the debt consolidation sector, proudly received the 2025 Excellence in Customer Service Award from the Business Intelligence Group. This accolade highlights the organization's unwavering commitment to transforming the lives of its clients by providing exceptional onboarding and...

Continue Reading
Understanding Bitcoin's Recent Price Fluctuations and Trends

Updated Category News Views 387

Bitcoin Faces Recent Price Challenges Bitcoin has experienced a 6% drop over the past month; nonetheless, it continues to be in a macro bull market. This resilience makes it outperform many other investment options as the cryptocurrency world evolves. What To Make of Recent Market Trends? Understanding Market Dynamics Notable crypto analyst Ali Martinez has pointed out...

Continue Reading
Chudnovsky Law Welcomes Brian D. Bill as New License Defense Attorney

Updated Category News Views 151

Chudnovsky Law's New Addition: Brian D. Bill Brian D. Bill has recently joined Chudnovsky Law, a distinguished law firm specializing in professional license defense. With California housing over 4.3 million licensed professionals, the need for expert defense in license investigations and enforcement cases is crucial. Brian D. Bill's Legal Background Mr. Bill brings...

Continue Reading